Press Room

CSF Europe 2024 - Compaction Simulation Forum

Start
Tuesday, June 04, 2024 - 16:49
End
Thursday, June 06, 2024 - 18:00
Location: Dublin, Ireland
CSF Conference João Henriques speaker | Hovione

CSF Workshop: Overcoming The Challenge of Poorly Soluble Drugs

This workshop delves into the complexities surrounding the formulation of poorly soluble drugs, a prevalent concern affecting a significant percentage of active pharmaceutical ingredients. Explore the scientific nuances of amorphous forms and their role in amorphous solid dispersions (ASDs), offering insights into enhanced solubility and dissolution. 

Our expert, João Henriques, Director, Oral Drug Product Development will lead the Workshop Session: Process Development and Scale-Up of Spray Drying

Join the session for an academic exploration where knowledge converges with scientific rigor, providing a thorough understanding of the formulation intricacies of poorly soluble drugs.

 

Key learnings:

  • Expand on your foundations and principles of spray drying for ASDs, from lab-scale development tools to the scale-up of processes and gain valuable insights on how ASDs improve the solubility and bioavailability of poorly soluble drugs.
  • Overcome solubility challenges with the best scale-up science, utilizing mechanistic and statistical modeling to delve into the impact of spray drying conditions and material attributes on downstream processing while leveraging our extensive expertise to ensure success from lab-scale to commercialization.

 

Do you want to know how Hovione can support your project? Schedule a meeting today.

schedule a meeting

 

 

 

 

Learn more about CSF Europe.

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026